ATE433318T1 - Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten - Google Patents

Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten

Info

Publication number
ATE433318T1
ATE433318T1 AT00300572T AT00300572T ATE433318T1 AT E433318 T1 ATE433318 T1 AT E433318T1 AT 00300572 T AT00300572 T AT 00300572T AT 00300572 T AT00300572 T AT 00300572T AT E433318 T1 ATE433318 T1 AT E433318T1
Authority
AT
Austria
Prior art keywords
administration
active ingredients
containing solid
solid amorphous
ingredients containing
Prior art date
Application number
AT00300572T
Other languages
English (en)
Inventor
Leah Elizabeth Appel
William John Curatolo
Scott Max Herbig
James Alan Schriver Nightingale
Avinash Govind Thombre
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE433318T1 publication Critical patent/ATE433318T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00300572T 1999-02-10 2000-01-26 Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten ATE433318T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11940699P 1999-02-10 1999-02-10

Publications (1)

Publication Number Publication Date
ATE433318T1 true ATE433318T1 (de) 2009-06-15

Family

ID=22384248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00300572T ATE433318T1 (de) 1999-02-10 2000-01-26 Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten

Country Status (6)

Country Link
EP (1) EP1027888B1 (de)
JP (1) JP2000229846A (de)
AT (1) ATE433318T1 (de)
BR (1) BR0000358A (de)
CA (1) CA2298238C (de)
DE (1) DE60042352D1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
CA2395231C (en) * 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
AU783685B2 (en) * 1999-12-23 2005-11-24 Pfizer Products Inc. Hydrogel-driven drug dosage form
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
UY26615A1 (es) 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
MXPA03011784A (es) * 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
WO2003000292A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
JP3980851B2 (ja) * 2001-08-30 2007-09-26 有限会社ゴトーコーポレーション 固型製剤、その製造方法、及び食品
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (de) 2001-09-21 2004-06-23 Egalet A/S Polymer-freigabe-system
TWI252111B (en) 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
KR100664822B1 (ko) 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
CN1688291A (zh) 2002-02-01 2005-10-26 辉瑞产品公司 含有固体药物分散体的即刻释放剂型
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
JP2005523260A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 圧力ノズルを用いた均質噴霧乾燥固体非晶質薬剤分散体の製造方法
EP1478349A1 (de) * 2002-02-21 2004-11-24 Amarin Development AB Methode zur freisetzung von nanopartikeln eines wirkstoffes aus einer diffusions-kontrollierten pharmazeutischen zubereitung zur oralen anwendung
US7605231B2 (en) 2002-04-26 2009-10-20 Yasuhiko Tabata Gelatin derivatives and high-molecular micelle comprising the derivatives
WO2003091283A1 (en) * 2002-04-26 2003-11-06 Nof Corporation Gelatin derivatives and high-molecular micelles comprising the same
CN1662226A (zh) * 2002-05-06 2005-08-31 兰贝克赛实验室有限公司 单室渗透控制药物输递系统
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004056359A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
CN102525993B (zh) 2003-04-24 2017-04-12 佳高泰克有限公司 具有限定内核几何形状的缓释片剂
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
KR20060033033A (ko) * 2003-08-04 2006-04-18 화이자 프로덕츠 인크. 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005030166A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Oros push-stick for controlled delivery of active agents
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
EP1845953A1 (de) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Darreichungsformen mit kontrollierter und unmittelbarer freisetzung von cholesterylester-transferprotein-hemmern und unmittelbarer freisetzung von hmg-coa-reduktase-hemmern
JP2006290821A (ja) * 2005-04-13 2006-10-26 Yoshiki Takeuchi 小孔カプセル
US8828438B2 (en) * 2005-05-31 2014-09-09 Bend Research, Inc. Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
SG174026A1 (en) 2006-08-03 2011-09-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
CN102573813B (zh) * 2009-08-18 2013-11-06 国立大学法人东北大学 持续药物传递系统
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US9364441B2 (en) * 2013-05-23 2016-06-14 Barlean's Organic Oils, Llc Rotary die system
JP6455293B2 (ja) * 2015-04-21 2019-01-23 ニプロ株式会社 セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
US20190099377A1 (en) * 2017-10-02 2019-04-04 Powder Pharma Coating Inc. Method for dry powder coating osmotic drug delivery system
AU2019311234A1 (en) * 2018-07-24 2021-02-04 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
WO2020020790A1 (de) * 2018-07-24 2020-01-30 Bayer Aktiengesellschaft Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
AU2020349524B2 (en) * 2019-09-18 2026-05-07 Bristol-Myers Squibb Company Dosage forms for Tyk2 inhibitors
MX2023000447A (es) * 2020-07-07 2023-04-20 Atxa Therapeutics Ltd Antagonista de receptor de tromboxano formulaciones.
EP4213813A1 (de) * 2020-09-18 2023-07-26 Bristol-Myers Squibb Company Dosierungsformen für tyk2-inhibitoren mit quellbaren kernen
AU2024344754A1 (en) 2023-09-21 2026-04-02 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
WO2026033474A1 (en) 2024-08-08 2026-02-12 Takeda Pharmaceutical Company Limited Deuterated compounds and uses thereof
CN121270318A (zh) * 2025-10-27 2026-01-06 广东海纳百川环保科技有限公司 一种有机肥料及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
JPS61227524A (ja) * 1985-03-30 1986-10-09 Tooa Eiyoo Kk プラゾシン製剤及びその製法
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
JPH04364129A (ja) * 1990-10-26 1992-12-16 Asahi Chem Ind Co Ltd ６−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法
WO1996019239A1 (en) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed

Also Published As

Publication number Publication date
JP2000229846A (ja) 2000-08-22
BR0000358A (pt) 2001-08-21
DE60042352D1 (de) 2009-07-23
CA2298238A1 (en) 2000-08-10
EP1027888B1 (de) 2009-06-10
CA2298238C (en) 2005-10-25
EP1027888A3 (de) 2001-02-28
EP1027888A2 (de) 2000-08-16

Similar Documents

Publication Publication Date Title
DE60042352D1 (de) Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
KR950703937A (ko) 안정한 서방성 경구 투여 조성물(Stable extended release oral dosage composition)
DE59802670D1 (de) Osmotisches arzneimittelfreisetzungssystem
ZA912793B (en) Pharmaceutical formulations
DE69614685D1 (de) Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
HK33793A (en) Oral sustained release forms of carbamazepine
DE69434515D1 (de) Formulierungen mit kontrollierte Abgabe überzogen mit wässrigen Dispersionen von Ethylcellulose
EP0641561B1 (de) Medizinische Vorrichtung zur Verabreichung von Aktivsubstanzen oder Arzneistoffen in sehr niedriger Dosis, insbesondere von homöopatischen Arzneistoffen
HU908477D0 (en) Process for the production of medical preparations with controlled content of active agents
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
TR200001998T1 (tr) Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
BR9811381A (pt) Processos para tratar um organismo de mamìfero para se obter um desejado efeito fisiológico ou farmacológico local ou sistêmico, para tratar um organismo de mamìfero quanto a retinite de citomegalovìrus, para fornecer administração controlada e prolongada de um agente eficaz na obtenção de um desejado efeito fisiológico ou farmacológico local ou sistêmico, e, sistema de aplicação de medicamento de liberação prolongada
ATE171617T1 (de) Arzneistoffabgabesysteme mit verzögerter freisetzung
CA2079316A1 (en) Iontophoretic drug delivery system with two-stage delivery profile
ATE248589T1 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
DE69840495D1 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
BG103552A (bg) Терапевтични средства
ATE326264T1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
DE60108255D1 (de) Clarithromycin enthaltende zubereitung mit verlängerter freisetzung
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DE60042168D1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
BRPI0307319B8 (pt) forma de dosagem oral para liberação controlada de droga e processo para sua preparação
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
WO1997018840A3 (en) Therapeutic delivery using compounds self-assembled into high axial ratio microstructures

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties